Semaglutide vs Dulaglutide

Semaglutide vs Dulaglutide: Overview

Semaglutide and dulaglutide are both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) that have become central to research into metabolic disease management. Semaglutide, marketed as Ozempic for type 2 diabetes and Wegovy for weight management, and dulaglutide, marketed as Trulicity, share the same receptor target but differ meaningfully in their molecular design, pharmacological potency, and clinical outcomes. For researchers seeking to understand what is the difference between Ozempic and Trulicity, the distinctions extend beyond branding into fundamental pharmacology.

Both compounds are modified analogs of the native GLP-1 hormone, engineered for extended half-lives that permit once-weekly subcutaneous administration. However, semaglutide incorporates a more extensive set of structural modifications that confer greater albumin binding affinity and resistance to enzymatic degradation, which research suggests may contribute to its enhanced clinical efficacy. The question of whether to choose semaglutide or dulaglutide — or indeed whether is Ozempic the same as Trulicity — has been examined directly in head-to-head clinical trials, most notably the SUSTAIN 7 study.

As clinicians and researchers compare Ozempic and Trulicity, the available evidence provides a detailed picture of how these two GLP-1 RAs differ in terms of glycaemic control, body weight reduction, cardiovascular outcomes, and tolerability. Understanding these differences is particularly relevant for those investigating switching from Trulicity to Ozempic, as the pharmacological profiles of these agents are not interchangeable despite their shared mechanism.

Mechanism of Action

Both semaglutide and dulaglutide function as agonists of the GLP-1 receptor, a class B G protein-coupled receptor expressed in pancreatic beta cells, the gastrointestinal tract, and the central nervous system. Activation of this receptor stimulates glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety through hypothalamic signalling pathways. These shared mechanisms underpin the glucose-lowering and weight-reducing effects observed with both compounds.

The key pharmacological distinction lies in their molecular architecture. Semaglutide is a modified human GLP-1 analog with a C-18 fatty diacid chain attached via a linker to lysine at position 26, which enables strong non-covalent binding to serum albumin. It also features an amino acid substitution at position 8 (Aib) that confers resistance to dipeptidyl peptidase-4 (DPP-4) cleavage. Dulaglutide, by contrast, consists of two modified GLP-1 analogs fused to the Fc fragment of human immunoglobulin G4 (IgG4), creating a larger fusion protein. This IgG4 fusion reduces renal clearance and extends the half-life, though through a fundamentally different mechanism than semaglutide’s albumin-binding approach.

Research suggests that semaglutide’s structural modifications result in higher receptor binding affinity and more potent activation of downstream signalling cascades compared with dulaglutide. This pharmacological distinction is thought to contribute to the differences observed in clinical efficacy, particularly regarding body weight reduction, where semaglutide has consistently demonstrated superior outcomes in comparative studies.

Clinical Evidence

The most significant direct comparison of semaglutide and dulaglutide comes from the SUSTAIN 7 trial, a phase 3b, open-label, randomised study that enrolled 1,201 participants with type 2 diabetes inadequately controlled on metformin. This trial compared semaglutide 0.5 mg and 1.0 mg once weekly against dulaglutide 0.75 mg and 1.5 mg once weekly over 40 weeks. Clinical data indicates that semaglutide demonstrated statistically superior reductions in HbA1c and body weight at both dose levels compared with the corresponding dulaglutide doses.

Specifically, semaglutide 0.5 mg reduced HbA1c by 1.5 percentage points versus 1.1 percentage points with dulaglutide 0.75 mg. At the higher doses, semaglutide 1.0 mg achieved a 1.8 percentage point reduction compared with 1.4 percentage points for dulaglutide 1.5 mg. These differences were statistically significant and clinically meaningful, establishing semaglutide’s superiority in glycaemic control within this head-to-head comparison. Post hoc analyses of the SUSTAIN 7 data have further characterised these differences across patient subgroups, confirming the consistency of the findings.

Subsequent indirect treatment comparisons have extended this analysis to higher doses of both agents. An indirect comparison by Pratley et al. examined semaglutide 1.0 mg against dulaglutide 3.0 and 4.5 mg, finding that semaglutide maintained its advantage in HbA1c reduction even when compared against higher dulaglutide doses. Similarly, an indirect treatment comparison using multilevel network meta-regression compared semaglutide 2.0 mg against dulaglutide 3.0 and 4.5 mg, further reinforcing the efficacy differential between these agents.

Efficacy Comparison

When researchers and clinicians assess whether is Trulicity better than Ozempic, the weight loss data provides a particularly clear distinction. In the SUSTAIN 7 trial, semaglutide 0.5 mg produced mean body weight reductions of 4.6 kg compared with 2.3 kg for dulaglutide 0.75 mg. At the higher doses, semaglutide 1.0 mg achieved 6.5 kg of weight loss versus 3.0 kg with dulaglutide 1.5 mg — more than double the weight reduction. This difference is especially relevant for those evaluating Ozempic or Trulicity for weight loss in the context of type 2 diabetes.

Real-world evidence has corroborated these trial findings. A large retrospective study in US veterans comparing liraglutide, semaglutide, and dulaglutide found that semaglutide was associated with greater reductions in HbA1c and body weight in routine clinical practice. A 2026 real-world retrospective study by Cetiner also confirmed the comparative effectiveness of semaglutide versus dulaglutide when combined with dietary intervention in newly diagnosed type 2 diabetes, demonstrating superior metabolic outcomes with semaglutide.

Regarding cardiovascular outcomes, both compounds have been investigated in dedicated cardiovascular outcome trials. The SUSTAIN 6 trial for semaglutide and the REWIND trial for dulaglutide both demonstrated cardiovascular benefits, with reductions in major adverse cardiovascular events (MACE). However, these trials used different comparators and enrolled different patient populations, making direct cardiovascular comparisons between the two agents more complex. Network meta-analyses have attempted to address this limitation, generally suggesting comparable cardiovascular protection with both agents, though methodological differences across trials warrant cautious interpretation.

Safety and Tolerability

The safety profiles of semaglutide and dulaglutide share common features characteristic of the GLP-1 receptor agonist class. Gastrointestinal adverse events — primarily nausea, vomiting, and diarrhoea — represent the most frequently reported side effects with both compounds. In the SUSTAIN 7 trial, gastrointestinal events occurred at broadly similar rates between the treatment groups, though nausea was numerically more common with semaglutide, particularly during the dose-escalation phase.

Clinical trials have shown that the overall discontinuation rates due to adverse events were relatively low for both agents, typically in the range of 5–10% across major trials. A systematic review of gastrointestinal adverse effects associated with anti-obesity medications in non-diabetic adults found that GLP-1 RAs as a class carry predictable GI tolerability profiles, with symptoms generally attenuating over time as patients reach maintenance doses. Real-world pharmacovigilance data examining differential safety signals across GLP-1 RAs has suggested that while the core adverse event profile is shared, there may be subtle differences in the rates of specific endocrine and dermatologic events between individual agents.

Both semaglutide and dulaglutide carry class-related warnings regarding potential risks of thyroid C-cell tumours (based on rodent data), pancreatitis, and gallbladder-related events. Research into ocular adverse events associated with GLP-1 receptor agonists has been an area of ongoing pharmacovigilance, though the clinical significance of reported signals remains under investigation.

Pharmacokinetics

Both semaglutide and dulaglutide are administered via once-weekly subcutaneous injection, but they achieve their extended duration of action through different pharmacokinetic strategies. Semaglutide has an elimination half-life of approximately 168 hours (seven days), achieved primarily through strong binding to albumin via its C-18 fatty diacid side chain. This albumin binding protects the molecule from enzymatic degradation and renal clearance, while the Aib substitution at position 8 provides resistance to DPP-4 cleavage.

Dulaglutide’s half-life is approximately 120 hours (five days), achieved through its IgG4 Fc fusion, which increases its molecular size and reduces renal clearance via FcRn-mediated recycling. The larger molecular size of dulaglutide (approximately 63 kDa versus approximately 4.1 kDa for semaglutide) results in different tissue distribution characteristics.

The pharmacokinetic differences between these agents have practical implications. Semaglutide’s longer half-life relative to its dosing interval provides more stable plasma concentrations throughout the dosing period. Semaglutide is available in both subcutaneous (Ozempic) and oral (Rybelsus) formulations, the latter employing the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) to enable gastric absorption. Dulaglutide is available only as a subcutaneous injection. Both agents reach steady-state concentrations after approximately four to five weeks of weekly dosing.

Current Research Status

Semaglutide holds FDA approval for type 2 diabetes (Ozempic, subcutaneous; Rybelsus, oral) and for chronic weight management (Wegovy, subcutaneous). Dulaglutide (Trulicity) is FDA-approved for type 2 diabetes and for reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors. Dulaglutide does not currently hold an approval specifically for weight management.

The clinical landscape continues to evolve, with research into higher-dose formulations and expanded indications for both compounds. Semaglutide has been studied at doses up to 2.4 mg weekly for weight management (Wegovy) and is under investigation in cardiovascular outcome trials (SELECT). For those considering switching from Trulicity to Ozempic, the clinical evidence base provides substantial data to inform such transitions, though individual patient factors must be considered. Ongoing real-world studies continue to generate comparative effectiveness data between these agents across diverse patient populations and clinical settings.

Summary

The comparison of semaglutide and dulaglutide reveals two GLP-1 receptor agonists with a shared mechanism but meaningfully different clinical profiles. Head-to-head data from the SUSTAIN 7 trial and subsequent indirect treatment comparisons consistently demonstrate that semaglutide achieves greater reductions in both HbA1c and body weight compared with dulaglutide. The pharmacological basis for this difference lies in the distinct molecular design strategies employed: semaglutide’s albumin-binding approach versus dulaglutide’s IgG4 Fc fusion. Both agents share the class-typical gastrointestinal adverse event profile, with broadly similar tolerability. Both have demonstrated cardiovascular benefits in dedicated outcome trials. Research continues to expand the evidence base for both compounds, with ongoing studies examining broader metabolic outcomes and real-world effectiveness across diverse populations.

References

• Pratley RE et al. (2018). Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. The Lancet Diabetes & Endocrinology. PMID: 29397376
• Pratley RE et al. (2021). An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. Diabetes, Obesity and Metabolism. PMID: 34286894
• Pratley RE et al. (2020). Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open. PMID: 33199417
• Lingvay I et al. (2022). An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. The Journal of Clinical Endocrinology & Metabolism. PMID: 34922383
• Cetiner S. (2026). Comparative effectiveness of semaglutide and dulaglutide combined with hypocaloric diet in newly diagnosed type 2 diabetes: a retrospective real-world study. BMC Endocrine Disorders. PMID: 41832437
• Pham TP et al. (2026). Relative Efficacy of Next-Generation Incretin Therapies for Cardio-Renal Protection in Type 2 Diabetes: Evidence From a Network Meta-Analysis. Diabetes, Obesity & Metabolism. PMID: 41804851
• Lee N and Kim Y. (2026). Not All GLP-1 Receptor Agonists Are Alike: Real-World Evidence of Differential Endocrine and Dermatologic Safety. Diabetes/Metabolism Research and Reviews. PMID: 41886296
• Nong K et al. (2025). Medications for adults with type 2 diabetes: a living systematic review and network meta-analysis. BMJ. PMID: 40813122